Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial.

Wirsching HG, Tabatabai G, Roelcke U, Hottinger AF, Jörger F, Schmid A, Plasswilm L, Schrimpf D, Mancao C, Capper D, Conen K, Hundsberger T, Caparrotti F, von Moos R, Riklin C, Felsberg J, Roth P, Jones DTW, Pfister S, Rushing EJ, Abrey L, Reifenberger G, Held L, von Deimling A, Ochsenbein A, Weller M.

Ann Oncol. 2018 Jun 1;29(6):1423-1430. doi: 10.1093/annonc/mdy120.

PMID:
29648580
2.

Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management.

Astaras C, de Micheli R, Moura B, Hundsberger T, Hottinger AF.

Curr Neurol Neurosci Rep. 2018 Feb 1;18(1):3. doi: 10.1007/s11910-018-0810-1. Review.

PMID:
29392441
3.

Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.

Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, Taillibert S, Toms SA, Honnorat J, Chen TC, Sroubek J, David C, Idbaih A, Easaw JC, Kim CY, Bruna J, Hottinger AF, Kew Y, Roth P, Desai R, Villano JL, Kirson ED, Ram Z, Stupp R.

JAMA Oncol. 2018 Apr 1;4(4):495-504. doi: 10.1001/jamaoncol.2017.5082.

4.

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.

Hottinger AF, Ben Aissa A, Espeli V, Squiban D, Dunkel N, Vargas MI, Hundsberger T, Mach N, Schaller K, Weber DC, Bodmer A, Dietrich PY.

Br J Cancer. 2018 Mar 20;118(6):e10. doi: 10.1038/bjc.2017.469. Epub 2018 Jan 9.

5.

[Revised WHO classification 2016 of gliomas : what's new ?]

Brouland JP, Hottinger AF.

Rev Med Suisse. 2017 Oct 18;13(579):1805-1809. French.

PMID:
29064198
6.

Extra central nervous system metastases from glioblastoma: a new possible trigger event?

Simonetti G, Silvani A, Fariselli L, Hottinger AF, Pesce GA, Prada F, Gaviani P.

Neurol Sci. 2017 Oct;38(10):1873-1875. doi: 10.1007/s10072-017-3036-0. Epub 2017 Jun 24.

PMID:
28647829
7.

Current management of low-grade gliomas.

Hottinger AF, Hegi ME, Baumert BG.

Curr Opin Neurol. 2016 Dec;29(6):782-788. Review.

PMID:
27676279
8.

Neurologic complications of immune checkpoint inhibitors.

Hottinger AF.

Curr Opin Neurol. 2016 Dec;29(6):806-812. Review.

PMID:
27653290
9.

Neurooncology: a Swiss army knife specialty.

Hottinger AF.

Curr Opin Neurol. 2016 Dec;29(6):781. No abstract available.

PMID:
27653289
10.

Tumor treating fields: a novel treatment modality and its use in brain tumors.

Hottinger AF, Pacheco P, Stupp R.

Neuro Oncol. 2016 Oct;18(10):1338-49. doi: 10.1093/neuonc/now182. Review.

11.

Recent advances in the management of atypical meningiomas.

Messerer M, Richoz B, Cossu G, Dhermain F, Hottinger AF, Parker F, Levivier M, Daniel RT.

Neurochirurgie. 2016 Aug;62(4):213-22. doi: 10.1016/j.neuchi.2016.02.003. Epub 2016 Jun 28. Review.

PMID:
27370103
12.

[Acute neurorehabilitation in neurooncology: Swiss Pilot Project and review of the litterature].

Diserens K, Robert JP, Pellet C, Berney L, Levivier M, Hottinger AF.

Rev Med Suisse. 2016 Apr 27;12(516):848, 850-2. Review. French.

PMID:
27281944
13.

[Neurological complications of anticancer treatments].

Hottinger AF, Perez L, Hägele-Link S, Hundsberger T.

Rev Med Suisse. 2016 Apr 27;12(516):840-3. Review. French.

PMID:
27281942
14.

[Multidisciplinar approach to the management of gliomas].

Moura B, Migliorini D, Bourhis J, Daniel R, Levivier M, Hottinger AF.

Rev Med Suisse. 2016 Apr 27;12(516):821-5. French.

PMID:
27281939
15.

Neuro-oncologie: la quintessence de la multidisciplinarité.

Hottinger AF, Kleinschmidt A, Du Pasquier R.

Rev Med Suisse. 2016 Apr 27;12(516):819. French. No abstract available.

PMID:
27281938
16.

Weekly Multi-agent Chemotherapy (CMF-b) for Advanced Non-melanoma Skin Cancer.

Espeli V, Ruegg E, Hottinger AF, Modarressi A, Dietrich PY.

Anticancer Res. 2016 May;36(5):2359-64.

PMID:
27127144
17.

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.

Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z.

JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669.

PMID:
26670971
18.

Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes.

Hundsberger T, Hottinger AF, Roelcke U, Roth P, Migliorini D, Dietrich PY, Conen K, Pesce G, Hermann E, Pica A, Gross MW, Brügge D, Plasswilm L, Weller M, Putora PM.

J Neurooncol. 2016 Jan;126(1):175-83. doi: 10.1007/s11060-015-1957-0. Epub 2015 Oct 12.

19.

Recent developments and controversies in primary central nervous system lymphoma.

Hottinger AF, Alentorn A, Hoang-Xuan K.

Curr Opin Oncol. 2015 Nov;27(6):496-501. doi: 10.1097/CCO.0000000000000233. Review.

PMID:
26371780
20.

Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology.

Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Rudà R, Schlegel U, Siegal T, Soussain C, Abacioglu U, Cassoux N, Deckert M, Dirven CM, Ferreri AJ, Graus F, Henriksson R, Herrlinger U, Taphoorn M, Soffietti R, Weller M; European Association for Neuro-Oncology Task Force on Primary CNS Lymphoma.

Lancet Oncol. 2015 Jul;16(7):e322-32. doi: 10.1016/S1470-2045(15)00076-5. Review.

21.

[Low-grade gliomas in adults].

Kratzsch T, Gautschi OP, Kuhn SA, Hottinger AF, Hildebrandt G, Stienen MN.

Praxis (Bern 1994). 2014 Nov 12;103(23):1385-96. doi: 10.1024/1661-8157/a001835. Review. German.

PMID:
25391745
22.

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.

Hottinger AF, Aissa AB, Espeli V, Squiban D, Dunkel N, Vargas MI, Hundsberger T, Mach N, Schaller K, Weber DC, Bodmer A, Dietrich PY.

Br J Cancer. 2014 May 27;110(11):2655-61. doi: 10.1038/bjc.2014.209. Epub 2014 May 1. Erratum in: Br J Cancer. 2018 Jan 09;:.

23.

Standards of care and novel approaches in the management of glioblastoma multiforme.

Hottinger AF, Stupp R, Homicsko K.

Chin J Cancer. 2014 Jan;33(1):32-9. doi: 10.5732/cjc.013.10207. Review.

24.

High-grade meningiomas: new avenues for drug treatment?

Preusser M, Berghoff AS, Hottinger AF.

Curr Opin Neurol. 2013 Dec;26(6):708-15. doi: 10.1097/WCO.0000000000000035. Review.

PMID:
24184974
25.

Isolated cerebral metastasis of a triceps muscle leiomyosarcoma: a case report.

Gautschi OP, Hottinger AF, Lobrinus JA, Schaller K, Bijlenga P.

Br J Neurosurg. 2014 Jun;28(3):400-2. doi: 10.3109/02688697.2013.829560. Epub 2013 Aug 19.

PMID:
23957777
26.

[Anti-neuronal antibodies: a rapidly developing field].

Zekeridou A, Rossetti AO, Hottinger AF, Du Pasquier RA.

Rev Med Suisse. 2013 May 1;9(384):909-14. Review. French.

PMID:
23717899
27.

PET Imaging in Glioma: The Neuro-Oncologist's Expectations.

Hottinger AF, Levivier M, Negretti L, Homicsko K, Stupp R.

PET Clin. 2013 Apr;8(2):117-28. doi: 10.1016/j.cpet.2012.09.006. Epub 2012 Nov 28.

PMID:
27157943
28.

Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.

Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I.

Neuro Oncol. 2013 Feb;15(2):242-50. doi: 10.1093/neuonc/nos295. Epub 2012 Dec 14.

29.

Decision making and management of gliomas: practical considerations.

Hottinger AF, Homicsko K, Negretti L, Lhermitte B, Stupp R.

Ann Oncol. 2012 Sep;23 Suppl 10:x33-40.

PMID:
22987986
30.

A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients.

Hottinger AF, George AC, Bel M, Favet L, Combescure C, Meier S, Grillet S, Posfay-Barbe K, Kaiser L, Siegrist CA, Dietrich PY; H1N1 Study Group.

Oncologist. 2012;17(3):436-45. doi: 10.1634/theoncologist.2011-0342. Epub 2012 Feb 21.

31.

Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, DeAngelis LM, Holland EC, Hormigo A.

Neuro Oncol. 2011 Nov;13(11):1244-51. doi: 10.1093/neuonc/nor117. Epub 2011 Aug 10.

32.

Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas.

Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, Deangelis LM, Holland EC, Hormigo A.

J Neurooncol. 2011 Dec;105(3):607-12. doi: 10.1007/s11060-011-0628-z. Epub 2011 Jun 28.

PMID:
21710351
33.

Delayed but Complete Response following Oral Temozolomide Treatment in Melanoma Leptomeningeal Carcinomatosis.

Hottinger AF, Favet L, Pache JC, Martin JB, Dietrich PY.

Case Rep Oncol. 2011 Apr 6;4(1):211-5. doi: 10.1159/000327699.

34.

Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.

Hofer S, Elandt K, Greil R, Hottinger AF, Huber U, Lemke D, Marosi C, Ochsenbein A, Pichler J, Roelcke U, Weder P, Zander T, Wick W, Weller M.

Acta Oncol. 2011 Jun;50(5):630-5. doi: 10.3109/0284186X.2011.572913. Epub 2011 Apr 18.

PMID:
21495907
35.

YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma.

Hottinger AF, Iwamoto FM, Karimi S, Riedel E, Dantis J, Park J, Panageas KS, Lassman AB, Abrey LE, Fleisher M, Holland EC, DeAngelis LM, Hormigo A.

Ann Neurol. 2011 Jul;70(1):163-9. doi: 10.1002/ana.22360. Epub 2011 Mar 9.

PMID:
21391238
36.

Neurooncology of familial cancer syndromes.

Hottinger AF, Khakoo Y.

J Child Neurol. 2009 Dec;24(12):1526-35. doi: 10.1177/0883073809337539. Review.

PMID:
19955345
37.

Neurological outcome of long-term glioblastoma survivors.

Hottinger AF, Yoon H, DeAngelis LM, Abrey LE.

J Neurooncol. 2009 Dec;95(3):301-305. doi: 10.1007/s11060-009-9946-9. Epub 2009 Jun 26.

PMID:
19557499
38.

Neuro-oncology of Neurofibromatosis Type 1.

Hottinger AF, Khakoo Y.

Curr Treat Options Neurol. 2009 Jul;11(4):306-14.

PMID:
19523356
39.

Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers.

Stupp R, Hottinger AF, van den Bent MJ, Dietrich PY, Brandes AA.

Ann Oncol. 2008 Sep;19 Suppl 7:vii209-16. doi: 10.1093/annonc/mdn474. No abstract available.

PMID:
18790951
40.

[Therapeutic strategies for the management of gliomas].

Hottinger AF, Stupp R.

Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):523-30. doi: 10.1016/j.neurol.2008.03.012. Epub 2008 May 13. Review. French.

PMID:
18565350
41.

Management of malignant glioma--quo vadis?

Stupp R, Hottinger AF.

Onkologie. 2008 Jun;31(6):300-2. doi: 10.1159/000134024. Epub 2008 May 27. No abstract available.

42.

Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma.

Hottinger AF, DeAngelis LM, Yahalom J, Abrey LE.

Neurology. 2007 Sep 11;69(11):1178-82.

PMID:
17846417
43.

Update on the management of familial central nervous system tumor syndromes.

Hottinger AF, Khakoo Y.

Curr Neurol Neurosci Rep. 2007 May;7(3):200-7. Review.

PMID:
17488585
44.

Combined femoral and obturator neuropathy caused by synovial cyst of the hip.

Stuplich M, Hottinger AF, Stoupis C, Sturzenegger M.

Muscle Nerve. 2005 Oct;32(4):552-4.

PMID:
15948204
45.
46.

Cellular xenotransplantation.

Aebischer P, Hottinger AF, Déglon N.

Nat Med. 1999 Aug;5(8):852. No abstract available.

PMID:
10426290
47.

Treatment of diseases of the central nervous system using encapsulated cells.

Hottinger AF, Aebischer P.

Adv Tech Stand Neurosurg. 1999;25:3-20. Review. No abstract available.

PMID:
10370715
48.
49.

Amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam: quantitative neuropathology, immunohistochemical analysis of neuronal vulnerability, and comparison with related neurodegenerative disorders.

Hof PR, Nimchinsky EA, Buée-Scherrer V, Buée L, Nasrallah J, Hottinger AF, Purohit DP, Loerzel AJ, Steele JC, Delacourte A, et al.

Acta Neuropathol. 1994;88(5):397-404.

PMID:
7847067

Supplemental Content

Loading ...
Support Center